Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 7/20 | 0.82 |
| ▸ | SERPINE1 | P05121 | 6/20 | 0.75 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | DHODH | Q02127 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268029 | 0.90 | ACLY (1.00) | ACLYSERPINE1SUCNR1MAPTDHODH | |
| Lithium Ion SCHEMBL7146523 | 0.88 | ACLY (0.68) | ACLYSERPINE1SUCNR1MAPTDHODH | |
| SCHEMBL7038564 | 0.87 | ACLY (0.67) | ACLYSERPINE1SUCNR1MAPTKDM4E | |
| SCHEMBL16496264 | 0.86 | SERPINE1 (0.76) | ACLYSERPINE1SUCNR1MAPTAKR1C4 | |
| SCHEMBL421010 | 0.86 | SERPINE1 (1.00) | SERPINE1SUCNR1DHODHKDM4ENPSR1 | |
| SCHEMBL13802449 | 0.85 | ACLY (0.72) | ACLYSERPINE1SUCNR1MAPTDHODH | |
| SCHEMBL1954779 | 0.85 | MEN1 (0.72) | ACLYSERPINE1SUCNR1MAPTPTPN1 | |
| SCHEMBL415869 | 0.83 | SERPINE1 (1.00) | ACLYSERPINE1SUCNR1MAPTKDM4E | |
| SCHEMBL5950666 | 0.83 | DHODH (0.72) | ACLYSERPINE1SUCNR1MAPTPTPN1 | |
| SCHEMBL7038130 | 0.82 | SERPINE1 (0.70) | ACLYSERPINE1SUCNR1PTPN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | claimed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073862-A1 | Compounds | PPARG, PPARA, PPARD | ACLY 451/4885SERPINE1 1107/4885SUCNR1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.